Jian Fang

Beijing Cancer Hospital

Beijing

China

SCHOLARLY PAPERS

2

DOWNLOADS

68

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (2)

1.

HS-10296 – A Novel Third Generation EGFR Tyrosine Kinase Inhibitor: Results of the First-in-Human Phase 1 Trial in Patients with Previously Treated EGFR Mutant Advanced Non-Small-Cell Lung Cancer

Number of pages: 160 Posted: 12 Dec 2019
National Taiwan University - Department of Oncology, University of Colorado, Aurora, Chang Gung University - Chang Gung Memorial Hospital, Zhejiang University, Nanjing University of Chinese Medicine (NJUCM) - Jiangsu Province Hospital of Traditional Chinese Medicine, National Yang Ming University - Taipei Veterans General Hospital, Taichung Veterans General Hospital, Taipei Medical University, Huazhong University of Science and Technology (Formerly Tongi Medical University) - Tongji Medical College, Chang Gung University - Chang Gung Memorial Hospital, Beverly Hills Cancer Center, National Cheng Kung University - Department of Internal Medicine, Central South University - Department of Medical Oncology, Beijing Cancer Hospital, Beijing Cancer Hospital, Central South University - Hunan Cancer Hospital, University Cancer & Blood Center, LLC, Sichuan University - West China Hospital, Zhejiang University - Department of Medical Oncology, Pacific Cancer Medical Center, Inc., University of California, San Diego (UCSD), Dartmouth College - Dartmouth-Hitchcock Medical Center, University of Miami - Sylvester Comprehensive Cancer Center, University of Texas Medical Branch-Galveston, MultiCare Institute for Research and Innovation, Baptist Healthcare Systems, Inc., China Medical University, Shanghai Jiao Tong University (SJTU) - Shanghai Chest Hospital and Shanghai Jiao Tong University (SJTU) - Shanghai Chest Hospital
Downloads 43 (462,606)

Abstract:

Loading...

epidermal growth factor receptor; mutated; non-small-cell lung cancer; phase 1 trial; safety

2.

A Phase 1b Study of Savolitinib Plus Gefitinib for Patients with EGFR-Mutated MET-Amplified Advanced Non-Small-Cell Lung Cancer

Number of pages: 40 Posted: 20 Jan 2020
Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Beijing Cancer Hospital, Nanjing Medical University - Department of Oncology, Fudan University, Harbin Medical University - Cancer Hospital, Guangzhou Medical University - First Affiliated Hospital, Jilin University (JLU) - First Affiliated Hospital, Government of the People's Republic of China - 307th Hospital, Central South University - Hunan Cancer Hospital, Tongji University - Shanghai Pulmonary Hospital, Soochow University - First Affiliated Hospital, AstraZeneca Pharmaceuticals - United States, AstraZeneca Pharmaceuticals - United States, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - China and Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute
Downloads 25 (552,180)

Abstract:

Loading...

Savolitinib; Gefitinib; EGFR-TKI; NSCLC; China; MET